March 26, 2019
UCB Japan and its partner Daiichi Sankyo launched an intravenous infusion version of their anti-epilepsy drug Vimpat (lacosamide) on March 25 for the treatment of partial onset seizures in epilepsy patients with or without secondary generalization, the two companies said...read more